M.KaulichM.ShapiroG
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Despite the objective improvements, only 26.7% (Group A) and 14.3% (Group B) rated results "good" or "excellent." This highlights the gap between measurable hair count increases and subjective satisfaction patients often need to see dramatic visual change to feel satisfied, which may require longer treatment or combination approaches
Michael Somenek, a clinical investigator in the groundbreaking Galderma study, notes that as medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. The Science Behind Facial Changes with GLP-1 Medications The 2025 Galderma clinical trial confirms what weve been observing in our practice at Aestha Clinic
Michael was great to work with
Shirleen Bautista, CEO of Ishin Beauty Frequently Asked Questions Is glutathione safe while breastfeeding
